Fundraising Fox
/People
Sign in

Peter Van Vlasselaer

Investor

Venture Partner at +ND Capital · Board director at Blade Therapeutics

Find your path to Peter

23 people in our graph can introduce you to Peter.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Gary Patou to introduce you to Peter

You →Gary · together at Blade Therapeutics →Peter

Ask Jamie Chen to introduce you to Peter

You →Jamie · together at Blade Therapeutics →Peter

Ask Sam Okafor to introduce you to Peter

You →Sam · 10 people · together at +ND Capital →Peter

Sign up to find every way you can get introduced to Peter

  • Your email: the people you already email who know Peter
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Peter
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

Joined +ND Capital in 2019 as a venture partner. A biotech executive, he was founder and CEO of ARMO Biosciences (acquired by Eli Lilly) and led several other companies that were acquired. He holds a PhD in Immunology from KU Leuven.

Contact· self-published, not guessed

Board director at Blade Therapeutics

Intro paths

→

In turn, Peter can intro founders to Blade Therapeutics's investors below.

Blade Therapeutics's investors · 7

+ND CapitalWoodside · $540K – $5.4M checks · since 2016Bay City CapitalSan Rafael · $5M – $10M checksDeerfield Management CompanyNew YorkMPM BioImpactBoston · $1M – $15M checks · since 2016Osage University PartnersBala CynwydOUP (Osage University Partners)Bala Cynwyd · $1M – $20M checksPfizer Venture Investments$5M – $20M checks

Deals · 2

RgenixBoard seat

via +ND Capital · filed Feb 2021 · $11M raise

Blade TherapeuticsBoard seat

via +ND Capital · filed Oct 2019 · $50M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at +ND Capital

Aditya Rajagopal
Venture Partner at +ND Capital
Alison Palmer
Vice President of the General Partner at +ND Capital
André Châtelain
Advisor at +ND Capital
Aymeric Sallin
Founder and CEO at +ND Capital
Carl Pabo
Advisor at +ND Capital
Cathleen O’Connor
Executive Assistant at +ND Capital
Eric Moessinger
Partner at +ND Capital
Gabriela Ecco
Principal at +ND Capital

Frequently asked questions

Who is Peter Van Vlasselaer?
Joined +ND Capital in 2019 as a venture partner. A biotech executive, he was founder and CEO of ARMO Biosciences (acquired by Eli Lilly) and led several other companies that were acquired. He holds a PhD in Immunology from KU Leuven.
Where does Peter Van Vlasselaer work?
Peter Van Vlasselaer is Venture Partner at +ND Capital and Board director at Blade Therapeutics.
What boards does Peter Van Vlasselaer sit on?
Peter Van Vlasselaer holds tracked board seats at Blade Therapeutics, Rgenix.